FORT LAUDERDALE, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII),...
MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global...
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
FDA confirms that SciSparc’s study may proceed following the application submission a month ago TEL AVIV, Israel, Sept. 23, 2024...
The Phase 2b trial will enroll 5,000 subjects across clinical sites in the US and UKSAN DIEGO, Sept. 23, 2024...
Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for...
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET...
FORT LEE, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., today...
GARDEN CITY, N.Y., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
- Target of 92 evaluable patients (46 in each of the control and VCN-01 treatment arms) enrolled across 15 sites in...
Preclinical data for 4D-710 for cystic fibrosis lung disease in combination with CFTR modulators to be presented in a poster...
Strong improvement in State-Trait Anger Expression Inventory 2 (STAXI-2) Trait Anger, a measure of agitation and aggression, at Weeks 8–12...
The New Statements Guide the Foundation’s 2025-2028 Strategic PlanBOWIE, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- After more than 50...
CHARLESTOWN, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences...
LONDON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Spur Therapeutics, formerly Freeline Therapeutics, today announced that Chief Executive Officer Michael Parini...
BOSTON, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies,...
Health plan focuses on evolving community needs while renewing longstanding commitment to address inequities, promote greater healthEAGAN, Minn., Sept. 23,...
New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential...
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnectSAN DIEGO, Sept. 23, 2024...
New certification program features generative and conversational AI developed in-house, setting a new standard in healthcare training Program's AI-based characters...